Hensley Michael, Ray Cheryl
University of Newcastle, Newcastle, NSW, Australia.
BMJ Clin Evid. 2009 Jun 4;2009:2301.
Sleep apnoea is the popular term for obstructive sleep apnoea-hypopnoea syndrome (OSAHS). OSAHS is abnormal breathing during sleep that causes recurrent arousals, sleep fragmentation, excessive daytime sleepiness, and nocturnal hypoxaemia. Apnoea may be "central", in which there is cessation of inspiratory effort, or "obstructive", in which inspiratory efforts continue but are ineffective because of upper airway obstruction. OSAHS affects up to 4% of men and 2% of women in the USA, with obesity being a major determinant.
We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatment for severe obstructive sleep apnoea-hypopnoea syndrome? What are the effects of treatment for non-severe obstructive sleep apnoea-hypopnoea syndrome? We searched: Medline, Embase, The Cochrane Library, and other important databases up to May 2008 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
We found 43 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
In this systematic review we present information relating to the effectiveness and safety of the following interventions: nasal continuous positive airway pressure (CPAP); measures aimed at improving compliance with CPAP; oral appliances; and weight loss.
睡眠呼吸暂停是阻塞性睡眠呼吸暂停低通气综合征(OSAHS)的通俗说法。OSAHS是睡眠期间的异常呼吸,会导致反复觉醒、睡眠片段化、日间过度嗜睡和夜间低氧血症。呼吸暂停可能是“中枢性的”,即吸气努力停止;或者是“阻塞性的”,即吸气努力持续但由于上气道阻塞而无效。在美国,OSAHS影响高达4%的男性和2%的女性,肥胖是一个主要决定因素。
我们进行了一项系统评价,旨在回答以下临床问题:重度阻塞性睡眠呼吸暂停低通气综合征的治疗效果如何?非重度阻塞性睡眠呼吸暂停低通气综合征的治疗效果如何?我们检索了:截至2008年5月的Medline、Embase、Cochrane图书馆及其他重要数据库(临床证据综述会定期更新;请查看我们的网站获取本综述的最新版本)。我们纳入了来自美国食品药品监督管理局(FDA)和英国药品及医疗保健产品监管局(MHRA)等相关组织的危害警示。
我们找到了43项符合我们纳入标准的系统评价、随机对照试验或观察性研究。我们对干预措施的证据质量进行了GRADE评估。
在本系统评价中,我们提供了以下干预措施的有效性和安全性相关信息:鼻持续气道正压通气(CPAP);旨在提高CPAP依从性的措施;口腔矫治器;以及减肥。